Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen
Translated title of the contribution
:
Treatment of BRAF-mutated metastatic melanoma
Tessa Bystrup Boyles,
Inge Marie Svane
, Lars Bastholt, Henrik Schmidt
Department of Clinical Medicine
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment of BRAF-mutated metastatic melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Metastatic Melanoma
100%
Skin Cancer
66%
MEK Inhibitor (MEKi)
66%
Acquired Resistance
33%
Cancer Mortality
33%
Treatment Failure
33%
Melanoma
33%
BRAF Inhibitor (BRAFi)
33%
Denmark
33%
Improved Outcomes
33%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Skin Cancer
66%
Mitogen Activated Protein Kinase Kinase Inhibitor
66%
Melanoma
33%